McKesson (MCK) Stock Forecast & Price Target

Q: What analysts cover McKesson?

McKesson has been rated by research analysts at Barclays , Citigroup , Evercore , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , TD Cowen , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$887.65 -20.34 (-2.24%)

Closing price 03:59 PM Eastern

Extended Trading

$897.50 +9.85 (+1.11%)

As of 06:11 PM Eastern

Compare

McKesson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
4

Buy
14

Based on 18 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for MCK.

Consensus Price Target

$973.44
9.66% Upside

According to the 18 analysts' twelve-month price targets for McKesson, the average price target is $973.44. The highest price target for MCK is $1,085.00, while the lowest price target for MCK is $845.00. The average price target represents a forecasted upside of 9.66% from the current price of $887.65.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MCK Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	9 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$973.44	$968.93	$960.53	$725.10
Forecasted Upside	9.66% Upside	11.15% Upside	21.71% Upside	4.10% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

McKesson Stock vs. The Competition

Type	McKesson	Healthcare Companies	Broader Market
Consensus Rating Score	2.78	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	7.96% Upside	898.84% Upside	15.04% Upside
News Sentiment Rating	Positive News See Recent MCK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/4/2026	Weiss Ratings 5 of 5 stars		Upgrade	Buy (B-) ➝ Buy (B)
8/19/2026	Barclays 3 of 5 stars	Glen Santangelo Not Rated	Boost Target	Overweight	$925.00 ➝ $1,000.00	+14.98%
8/19/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Initiated Coverage	Sector Perform	$845.00	-2.84%
8/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$812.00 ➝ $933.00	+6.26%
8/7/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$1,015.00	+20.43%
8/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
8/6/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$989.00 ➝ $1,006.00	+15.47%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,050.00 ➝ $1,080.00	+23.97%
7/24/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$945.00 ➝ $1,000.00	+21.26%
Get the Latest News and Ratings for MCK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.
5/8/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$875.00	+15.73%
5/8/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$1,107.00 ➝ $1,015.00	+37.07%
4/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
4/6/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,040.00 ➝ $1,000.00	+16.29%
3/5/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$970.00	+4.12%
3/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$1,085.00	+16.60%
2/5/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Valiquette Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$880.00 ➝ $885.00	+7.98%
11/25/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/13/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Tanquilut Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$820.00 ➝ $900.00	+17.07%
4/4/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Sundaram Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:32 PM ET.

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 5, 2026. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

Here are some ways that investors could benefit from investing in McKesson Co.:

McKesson Co. recently reported strong quarterly results on August 5, 2026, beating consensus estimates with an EPS of $9.93 compared to the expected $9.56, while also exceeding revenue forecasts with $105.38 billion in sales, demonstrating robust operational performance and demand for its pharmaceutical distribution services.
The company has a low beta of 0.30, which indicates that its stock price tends to be less volatile than the overall market, making it a potentially stable investment option for investors seeking to reduce portfolio risk during periods of market uncertainty.
McKesson Co. recently increased its quarterly dividend to $0.94 per share, representing a 14.6% increase from the previous $0.82 payment, which signals management confidence in the company's financial health and provides a growing income stream for shareholders.
With a current stock price of $907.35, the stock is trading below its 52-week high of $999.00 and below the consensus analyst price target of $977.00, suggesting there may be room for price appreciation as the market digests recent positive earnings and guidance.
McKesson Co. has set its FY 2027 guidance at $44.20 to $45.00 in EPS, which is above the current consensus estimate of $44.65, indicating that management expects continued earnings growth and operational efficiency improvements in the coming year.

McKesson
Bear Case

Investors should be bearish about investing in McKesson Co. for these reasons:

Insiders have been selling shares, with CEO Brian Tyler selling 8,463 shares in July 2026 and 8,463 shares in June 2026, which could signal a lack of confidence in the stock's near-term performance or a desire to diversify personal holdings.
McKesson Co. has a negative return on equity of 253.21% for the most recent quarter, which is a significant red flag for investors as it indicates that the company is not efficiently using its equity to generate profits, potentially due to high debt levels or operational challenges.
The company's net margin is only 1.12%, which is relatively low for a large healthcare distribution company, suggesting that it may be facing significant cost pressures or pricing challenges that could limit its ability to grow profits in the future.
Some analysts have recently downgraded the stock, with Weiss Ratings cutting its rating from "buy (b)" to "buy (b-)" in July 2026 and Wall Street Zen downgrading it from "buy" to "hold" in June 2026, indicating that some investors are becoming more cautious about the stock's valuation and growth prospects.
McKesson Co. is facing potential regulatory scrutiny and operational risks due to a reported data breach, which could impact its relationships with healthcare partners and increase compliance costs, potentially affecting its bottom line and reputation.

MCK Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $973.44, with a high forecast of $1,085.00 and a low forecast of $845.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 9.66% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 1 upgrade and 1 downgrade by analysts.

McKesson has been rated by research analysts at Barclays, Citigroup, Evercore, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, TD Cowen, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "healthcare" companies. The consensus rating for McKesson is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MCK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With McKesson Recommendations

MarketBeat monitors more than a dozen sources for McKesson analyst ratings, with the most recent rating issued on 9/4/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

McKesson (MCK) Stock Forecast & Price Target